Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Regeneron (REGN) . This company, which is in the Zacks Medical - Biomedical and Genetics industry, shows potential for another earnings beat.This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters wa ...